An Epidemiologic Survey of Hospitalized Cases of Venous Thrombosis and Pulmonary Embolism in Young Women

Arthes, Federico G.

doi:10.2307/3349409

Cited by 7 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the funnel plot was asymmetric and there was evidence of bias based on both the Egger weighted regression method ( P = 0.000) and Begg’s rank correlation method ( P = 0.004). Based on 17 studies [13,44,45,47–58,63,65], similar results to that for non O/O comparisons were observed for group A relative to O (Fig. 2, pooled OR 1.63, 95% CI 1.40–1.89).…”

Section: Resultssupporting

confidence: 70%

“…Studies on CIAO were generally of good quality, although four did not define CIAO using modern imaging [21,41–43]. For VTE studies, the majority did not report detailed demographic data [44–57], whilst others failed to comprehensively adjust for potential population stratification [13,44–58], or employed an insufficient sample size [46,50,54,55].…”

Section: Resultsmentioning

confidence: 99%

“…Of the 21 studies included in the VTE analysis, 3 were carried out prospectively [49,50,61], 10 employed objective diagnosis [13,44,47–49,58,61–64] and 14 [13,45,46,50–52,54,57,58,61,63–66] used controls from a comparable population (Table S5). With the exception of three [45,52,57], all reported a significant increase in VTE risk with non‐O, with ORs from 1.26 to 3.92. Overall, the pooled OR was 1.79 (95% CI 1.56–2.05), indicating a significant increase in VTE risk associated with non‐O.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

ABO(H) blood groups and vascular disease: a systematic review and meta‐analysis

Bayoumi

Vickers

et al. 2008

Journal of Thrombosis and Haemostasis

366

329

View full text Add to dashboard Cite

To cite this article: Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. 2008; 6: 62-9. Summary. Background: Associations between vascular disease and ABO(H) blood groups have a long history, but no consensus exists regarding its magnitude and significance, or whether it relates to all disorders equally. An accurate calculation of risk would allow direct assessment of whether the effects of non-O status on thrombosis risk are of the magnitude predicted by its effect on von Willebrand factor/ FVIII levels. Methods and results: We conducted a systematic review and meta-analysis of studies reporting associations with non-O blood groups. This gave pooled odds ratios of 1.25 [95% confidence interval (CI) 1.14-1.36] for myocardial infarction (MI), 1.03 (95% CI 0.89-1.19) for angina, 1.45 (95% CI 1.35-1.56) for peripheral vascular disease, 1.14 (95% CI 1.01-1.27) for cerebral ischemia of arterial origin, and 1.79 (95% CI 1.56 to 2.05) for venous thromboembolism (VTE). However, restriction to prospective MI studies only did not confirm the association (OR 1.01; 95% CI 0.84-1.23), although these studies may have failed to capture early-onset disease. For VTE, using a combined group of OO/A 2 A 2 /A 2 O as index, the combination of A 1 A 1 /A 1 B/BB gave an OR of 2.44 (95% CI 1.79-3.33) and A 1 O/ BO/A 2 B an OR of 2.11 (95% CI 1.66-2.68). Conclusions: This study confirms the historical impression of linkage between some vascular disorders and non-O blood group status. Although the odds ratios are similar to those predicted by the effect of ABO(H) on von Willebrand factor levels, further work is required to assess risk prospectively and to refine the effect of reducing O(H) antigen expression on thrombosis. However, as non-O and particularly A 1 A 1 , A 1 B, BB constitute a significant proportion of the population attributable fraction of VTE, there may be a role for more widespread adoption of ABO(H) typing in testing strategies. J Thromb Haemost

show abstract

Section: Resultssupporting

confidence: 70%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

ABO(H) blood groups and vascular disease: a systematic review and meta‐analysis

Bayoumi

Vickers

et al. 2008

Journal of Thrombosis and Haemostasis

366

329

View full text Add to dashboard Cite

show abstract

“…All included studies provided data on the prevalence of blood groups in patients with VTE and in controls; six studies provided data on the prevalence of ABO genotypes in VTE patients and in controls 24,25,28,34,37 and five studies provided data on the prevalence of FVL and/or G20210A PTM in VTE patients and in controls. 23,27,30,32,37 There were 3 studies provided separate data on the prevalence of blood group in patients with unprovoked VTE, 27,47,48 whereas 10 studies provided separate data on the prevalence of blood group in patients with provoked VTE. 20,25,29,32,35,38,45,47,50 Study Quality VTE was described as objectively diagnosed in 22 studies [19][20][21][22]24,[26][27][28][30][31][32][33][34][35][36][37][40][41][42][43] and 37 studies were published in peer-reviewed journals.…”

Section: Study Characteristicsmentioning

confidence: 99%

Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature

Dentali

Sironi

Ageno

et al. 2012

Semin Thromb Hemost

203

175

View full text Add to dashboard Cite

It is well known that the ABO blood group exerts a major influence on hemostasis, as O blood group individuals have lower von Willebrand factor and factor VIII levels than non-O blood group subjects. To evaluate the possible clinical implication of the different ABO blood groups on the risk of developing venous thromboembolism (VTE), we conducted a meta-analysis of the existing literature. After an electronic search strategy using Medline and Embase and a manual review of abstract books of the International Society on Thrombosis and Haemostasis and of reference lists of all retrieved articles, we included in the systematic review 38 studies with 10,305 VTE cases. The prevalence of non-O blood group was significantly higher in VTE patients compared with controls with a resulting pooled odds ratio (OR) of 2.09 (95% confidence interval [CI], 1.83, 2.38; p < 0.00001). Similar findings were obtained when the genotypes A1O/BO/A2B (OR 1.73, 95% CI, 1.47, 2.05; p < 0.00001) and A1B/A1A1/BB (OR 1.87, 95% CI, 1.84, 2.44; p < 0.00001) were analyzed. The maximum VTE risk was observed in non-O-factor V Leiden patients (OR 7.60, 95% CI, 3.21, 17.99), while for G20210A prothrombin mutation it was not possible to perform a pooled analysis due to a paucity of published studies. Finally, the association between non-O blood group and VTE was weaker when provoked VTE cases were considered (OR 1.33, 95% CI, 1.18, 1.50), while it was substantially unchanged when unprovoked VTE cases were analyzed (OR 1.88, 95% CI, 1.42, 2.50). In conclusion, considering its prevalence, non-O blood group is a candidate to be one of the most important genetic risk factors for venous thrombosis.

show abstract

“…Oral contraceptive pills (OCP) and hormone replacement therapy, which are well-established risk factors for VTE, are more likely to be present in women who present with PE compared to men (14.8% women vs. 0.8% men; p < 0.001) [ 20 , 22 , 30 ]. Additionally, those on OCPs have been found to have a higher likelihood of right ventricular strain with PE compared to those who were not taking OCP ( p = 0.003) [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

Pulmonary Embolism in Women: A Systematic Review of the Current Literature

Thachil

Nagraj

Kharawala

et al. 2022

JCDD

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of death in women. Pulmonary embolism (PE) is the third most-common cause of cardiovascular death, after myocardial infarction (MI) and stroke. We aimed to evaluate the attributes and outcomes of PE specifically in women and explore sex-based differences. We conducted a systematic review of the literature using electronic databases PubMed and Embase up to 1 April 2022 to identify studies investigating PE in women. Of the studies found, 93 studies met the eligibility criteria and were included. The risk of PE in older women (especially >40 years of age) superseded that of age-matched men, although the overall age- and sex-adjusted incidence of PE was found to be lower in women. Risk factors for PE in women included age, rheumatologic disorders, hormone replacement therapy or oral contraceptive pills, pregnancy and postpartum period, recent surgery, immobilization, trauma, increased body mass index, obesity, and heart failure. Regarding pregnancy, a relatively higher incidence of PE has been observed in the immediate postpartum period compared to the antenatal period. Women with PE tended to be older, presented more often with dyspnea, and were found to have higher NT-proBNP levels compared to men. No sex-based differences in in-hospital mortality and 30-day all-cause mortality were found. However, PE-related mortality was higher in women, particularly in hemodynamically stable patients. These differences form the basis of future research and outlets for reducing the incidence, morbidity, and mortality of PE in women.

show abstract

An Epidemiologic Survey of Hospitalized Cases of Venous Thrombosis and Pulmonary Embolism in Young Women

Cited by 7 publications

References 1 publication

ABO(H) blood groups and vascular disease: a systematic review and meta‐analysis

ABO(H) blood groups and vascular disease: a systematic review and meta‐analysis

Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature

Pulmonary Embolism in Women: A Systematic Review of the Current Literature

Contact Info

Product

Resources

About